Impact of rituximab and half-dose CHOP as primary therapy for untreated symptomatic Waldenström Macroglobulinemia: review of a combined regimen of rituximab with an alkylating agent

BACKGROUND: Waldenström Macroglobulinemia (WM) is a rare subtype of indolent B-cell lymphoma, and prospective randomized studies on WM are scarce. The R-CHOP therapy [rituximab (R), cyclophosphamide, hydroxy-doxorubicin, vincristine, and prednisone] is a popular and recommended regimen for primary t...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekiguchi, Naohiro, Hamano, Airi, Kitagawa, Tomoko, Kurihara, Yuya, Ito, Kenichi, Kurimoto, Miwa, Watanabe, Kozo, Hirano, Kazuhiko, Noto, Satoshi, Yamada, Kazuaki, Takezako, Naoki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021562/
https://www.ncbi.nlm.nih.gov/pubmed/29963517
http://dx.doi.org/10.5045/br.2018.53.2.117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021562/
https://www.ncbi.nlm.nih.gov/pubmed/29963517
http://dx.doi.org/10.5045/br.2018.53.2.117

Ejemplares similares